Plant-based vaccines against human hepatitis B virus

Area of Science:

• Virology and Immunology
• Vaccine Development
• Biotechnology

Background:

• Hepatitis B virus (HBV) infection is a global health concern causing significant mortality and economic burden.
• Current HBV vaccines are subunit vaccines based on hepatitis B surface antigen (HBsAg), produced in yeast or mammalian cells.
• There is a need for alternative vaccine platforms, particularly for mucosal delivery, as HBV is sexually transmitted.

Purpose of the Study:

• To analyze the current data on the development of plant-based vaccines for hepatitis B.
• To explore the potential of plant-based systems for producing hepatitis B surface antigen (HBsAg).
• To evaluate the feasibility of developing mucosal HBV vaccines using plant-based technologies.

Main Methods:

• Review and analysis of existing scientific literature on plant-based vaccine development for HBV.
• Examination of studies involving the expression and purification of HBsAg in various plant systems.
• Assessment of immunogenicity data from preclinical studies of plant-derived HBsAg.

Main Results:

• Plant-based systems can express and assemble HBsAg particles with characteristics similar to those produced in yeast or mammalian cells.
• Studies have demonstrated the potential for inducing immune responses, including systemic and potentially mucosal immunity, with plant-derived HBsAg.
• Plant-based vaccine production offers advantages such as lower cost, scalability, and potentially enhanced safety profiles.

Conclusions:

• Plant-based vaccine technology presents a viable and promising avenue for the development of novel hepatitis B vaccines.
• Further research and clinical trials are warranted to fully realize the potential of plant-based HBV vaccines, especially for mucosal administration.
• This approach could contribute to more accessible and cost-effective strategies for controlling the global burden of hepatitis B infection.